

## REGULATION OF HUMAN ERYTHROCYTE HEXOKINASE BY GLUCOSE-1, 6-DIPHOSPHATE AND INORGANIC PHOSPHATE

Gert RIJKSEN and Gerard E. J. STAAL

*Haematological Department, Unit of Medical Enzymology, State University Hospital, Utrecht, The Netherlands*

Received 9 June 1977

### 1. Introduction

Considerable amounts of glucose 1, 6-diphosphate (Glc-1,6-P<sub>2</sub>) exist in mammalian erythrocytes [1–3], mainly as a result of the phosphoglucomutase reaction [2,3]. It is involved in glycolysis by its positive effects on phosphofructokinase [4] and pyruvate kinase [5] and by its inhibitory action on hexokinase [6,7]. The inhibition constants reported for hexokinase type I from human erythrocytes [6,7] are well in or below the range of the intracellular concentrations [1–3], suggesting a role for Glc-1,6-P<sub>2</sub> in regulation of hexokinase activity in vivo. In contrast Beitner et al. [8] reported that Glc-1,6-P<sub>2</sub> exerted a selective inhibitory effect on hexokinase type II and had no effect on type I hexokinase.

A striking pH-dependency of the inhibition by Glc-1,6-P<sub>2</sub> was reported by Rose and Warms [9] for hexokinase type II from Ehrlich-Lettré hyperdiploid cells and for hexokinase type I from Sarcoma 37 cells.

Recently we reported [10] that the inhibition of purified hexokinase from human erythrocytes by glucose 6-phosphate and fructose 6-phosphate is strongly regulated by inorganic phosphate. In this paper we show that the inhibition of human erythrocyte hexokinase by Glc-1,6-P<sub>2</sub> is similarly regulated by inorganic phosphate and that the same pH-dependency exists as reported by Rose and Warms [9] for hexokinase from Ehrlich-Lettré and Sarcoma 37 cells.

### 2. Materials and methods

Glucose 1,6-diphosphate (Glc-1,6-P<sub>2</sub>, tetracyclohexylammonium salt), ATP (disodium salt), NADP<sup>+</sup>

(disodium salt) and glucose-6-phosphate dehydrogenase were obtained from Boehringer, Mannheim. NaH<sub>2</sub>PO<sub>4</sub> (P<sub>i</sub>) and all other chemicals were of analytical grade or purity.

Human erythrocyte hexokinase was purified as reported earlier [11], with a specific activity of 35 U/mg of protein. The enzyme solution contained 0.05 M Tris-HCl (pH = 8.0), 0.5 M NaCl and 0.003 M  $\beta$ -mercaptoethanol.

Hexokinase activity was determined at 37°C in a system coupled with glucose-6-phosphate dehydrogenase as described before [10]. MgCl<sub>2</sub> was added in the concentrations necessary to maintain an excess of 5 mM Mg<sup>2+</sup> over ATP. The concentration of glucose was 10 mM. The pH of the assay buffer ranged from 6.8–8.3. All pH values were determined at 37°C in the complete reaction mixture. The reaction was started by adding 0.03 units of hexokinase. One unit of enzyme activity is defined as the amount of enzyme which catalyzes the formation of 1  $\mu$ mol of glucose 6-phosphate per min at 37°C.

Inhibition constants were calculated from double reciprocal plots of enzyme activity vs. [MgATP<sup>2-</sup>] in the presence and absence of Glc-1,6-P<sub>2</sub> at a concentration near the K<sub>i</sub>. These plots have been statistically treated as described before [12].

### 3. Results

Human erythrocyte hexokinase is inhibited by Glc-1,6-P<sub>2</sub> competitively with respect to MgATP<sup>2-</sup> (fig.1). The secondary plot of slope of the Lineweaver-Burke plots vs. inhibitor concentration is linear up to inhibitor concentrations of about twice the




Fig.1. Lineweaver-Burk plots of hexokinase activity vs.  $1/[MgATP^{2-}]$  at concentrations of Glc-1, 6-P<sub>2</sub> of 0.0 mM (●), 0.05 mM (Δ), 0.2 mM (□), 0.3 mM (×), 0.4 mM (■), 0.5 mM (▲) and 0.9 mM (○). pH = 7.7. Inset: Secondary plot of slope vs. added Glc-1, 6-P<sub>2</sub>.

$K_i$  (inset fig.1). At higher concentrations the curve bends upwards. Inorganic phosphate was able to overcome, at least partly, the inhibition by Glc-1, 6-P<sub>2</sub> (fig.2). This influence of P<sub>i</sub> is competitive with respect to Glc-1, 6-P<sub>2</sub>. A similar pattern of inhibition and a similar influence of P<sub>i</sub> was found either at pH 7.7 (figs.1 and 2) or at pH 7.15 (results not shown), although  $K_i$  Glc-1, 6-P<sub>2</sub> was much lower at pH 7.15 (see below).

Using modified Michaelis-Menten equations the influence of P<sub>i</sub> on the inhibition constant of an inhibitor could be described in terms of enzyme activity in presence and absence of inhibitor as a function of P<sub>i</sub> [10]. If P<sub>i</sub> competes completely with the inhibitor, the function equals  $f(P_i) = 1 + P_i/K_{P_i}$ . However the function describing the influence of P<sub>i</sub>

on the inhibitor by Glc-1, 6-P<sub>2</sub> is not linear (fig.3), reflecting the inability of P<sub>i</sub> to overcome the inhibition completely.  $K_i$  Glc-1, 6-P<sub>2</sub> is maximally increased by a factor of about 3 at pH 7.7 and by a factor of about 4 at pH 7.15 at higher concentrations of P<sub>i</sub>. From the linear part of the function the activation constant of P<sub>i</sub>,  $K_{P_i}$ , can be calculated. Up to concentrations of about 1 mM P<sub>i</sub> the activation constant of P<sub>i</sub> is approx. 0.8 mM at both pH values.

Figure 4 shows that the inhibition by Glc-1, 6-P<sub>2</sub> is pH dependent, the inhibition constant increases exponentially above pH 7.0. The inhibition was competitive towards  $MgATP^{2-}$  at all pH values tested. The inhibition by glucose 6-phosphate, fructose 6-phosphate and fructose 1,6-diphosphate, observed at pH 7.7 [10] was not pH-dependent.





Fig. 2. Influence of  $P_i$  on the inhibition by Glc-1, 6- $P_2$  at pH 7.7. The reciprocal of hexokinase activity is plotted vs. the reciprocal of  $[MgATP^{2-}]$  in the presence ( $\Delta, \blacktriangle, \circ, \blacksquare$ ) and absence ( $\bullet$ ) of 0.5 mM Glc-1, 6- $P_2$ . The concentrations of added phosphate are 0.0 mM ( $\bullet, \Delta$ ), 0.2 mM ( $\blacktriangle$ ), 0.8 mM ( $\circ$ ) and 5.0 mM ( $\blacksquare$ ).



#### 4. Discussion

The results show that the competitive inhibition of human erythrocyte hexokinase by Glc-1, 6- $P_2$  with respect to  $MgATP^{2-}$  is similarly regulated by phosphate as the inhibition by glucose-6-P and fructose-6-P described previously [10]. To explain the effects of  $P_i$  a model, proposed by Ellison et al. [13] for brain hexokinase, was modified: hexokinase exists in

Fig. 3. Influence of  $P_i$  on the inhibition by Glc-1, 6- $P_2$  by 0.5 mM Glc-1, 6- $P_2$  at pH 7.7 ( $\bullet$ ) and by 0.1 mM Glc-1, 6- $P_2$  at pH 7.15 ( $\circ$ ).  $f(P_i)$  is determined as defined in the text.  $[MgATP^{2-}]$  was kept constant at 0.5 mM.




Fig.4. Influence of pH on the inhibition constant of Glc-1,6-P<sub>2</sub>. The values for  $K_i$  and the standard error of  $K_i$  (brackets) are calculated as described in Materials and methods.

equilibrium between a free and a phosphate associated form with the same kinetic properties except in their ability to bind hexose-phosphate. The phosphate associated form has a reduced but still substantial affinity for the inhibitor. An alternative explanation of the results is the presence of two different enzymes, one with a high affinity for hexose-phosphate, being sensitive to regulation by  $P_i$ , one with a lower affinity for hexosephosphate being insensitive to  $P_i$ ; the  $K_m$   $MgATP^{2-}$  being the same for both enzymes. The secondary plot of fig.1, which is deviating from linearity at higher concentrations of Glc-1,6-P<sub>2</sub> is in favour of the latter model.

The pH-dependency of the inhibition of human erythrocyte hexokinase by Glc-1,6-P<sub>2</sub> is completely in agreement with the results of Rose and Warms [9] on hexokinase from Ehrlich-Létré and Sarcoma 37 cells. They argued that the loss of inhibition at higher pH is attributed to the appearance of an additional negative charge. The phosphate-group at the C<sub>1</sub>-atom is bound to the enzyme as a mono-anion but is excluded as a dianion.

At pH 7.2, the intracellular pH of the red blood cell, the inhibition constant of Glc-1,6-P<sub>2</sub> is about 50  $\mu$ M. This value is measured at a concentration of 5 mM of free  $Mg^{2+}$ . Under in vivo conditions this inhibition constant may even be lower, because intracellular concentrations of free  $Mg^{2+}$  (approx. 0.7 mM, ref. [14]) minimize the formation of  $Mg$ -Glc-1,6-P<sub>2</sub> ( $K_{diss} = 2.5$  mM), which is not inhibitory [9]. The value of  $K_i$  is well below the range of intracellular concentrations of Glc-1,6-P<sub>2</sub> (80–150)  $\mu$ M, ref. [1–3], suggesting an important role for Glc-1,6-P<sub>2</sub> in regulating hexokinase activity in vivo. From this data it is probable that Glc-1,6-P<sub>2</sub> is at least as important in regulating hexokinase activity in vivo as is glucose-6-P. Because  $P_i$  exerts its most pronounced effects in the range of its physiological concentration, the importance of  $P_i$  in regulating hexokinase activity is once more demonstrated.

The strong pH-dependency of the inhibition of human erythrocyte hexokinase by Glc-1,6-P<sub>2</sub> suggests that red cell glycolysis is influenced by pH not only at the phosphofructokinase step but also at the hexokinase step.

In glucosephosphate isomerase (GPI) deficiency increased levels of glucose 6-phosphate and an increased formation of glycogen in erythrocytes and liver are reported [15]. The latter suggests that in addition to the increased level of glucose-6-P the amount of Glc-1,6-P<sub>2</sub> might be increased too. Defective GPI thus may affect strongly the regulation of hexokinase, which may account for its strong impact on erythrocyte mechanism reflected in severe haemolysis. On the contrary the formation of  $P_i$  during glycogen formation will have a positive effect on hexokinase activity. Unfortunately there is little information available about the red cell contents of Glc-1,6-P<sub>2</sub> and  $P_i$  in GPI-deficiency.

### Acknowledgements

The Netherlands Foundation for Fundamental Medical Research (FUNGO) is acknowledged for partial financial support (Grant 13-39-12). Mrs E. L. Huisman-Backer Dirks is thanked for typing the manuscript.

**References**

- [1] Bartlett, G. R. (1968) *Biochim. Biophys. Acta* 156, 231–239.
- [2] Passonneau, J. V., Lowry, O. H., Schulz, D. W. and Brown, J. G. (1969) *J. Biol. Chem.* 244, 902–909.
- [3] Gerber, G., Winczuk, E. and Rapoport, S. (1973) *Acta Biol. Med. Germ.* 30, 759–771.
- [4] Rose, I. A. and Warms, J. V. B. (1974) *Biochem. Biophys. Res. Commun.* 59, 1333–1340.
- [5] Koster, J. F., Slee, R. G., Staal, G. E. J. and Van Berkel, Th. J. C. (1972) *Biochim. Biophys. Acta* 258, 763–768.
- [6] Gerber, G., Preissler, H., Heinrich, R. and Rapoport, S. M. (1974) *Eur. J. Biochem.* 45, 39–52.
- [7] Rose, I. A., Warms, J. V. B. and Kosow, D. P. (1974) *Arch. Biochem. Biophys.* 164, 729–735.
- [8] Beitner, R., Haberman, S. and Livni, L. (1975) *Biochim. Biophys. Acta* 397, 355–369.
- [9] Rose, I. A. and Warms, J. V. B. (1975) *Arch. Biochem. Biophys.* 171, 678–681.
- [10] Rijksen, G. and Staal, G. E. J. (1977) *Biochim. Biophys. Acta* (in press).
- [11] Rijksen, G. and Staal, G. E. J. (1976) *Biochim. Biophys. Acta* 445, 330–341.
- [12] Rijksen, G. and Staal, G. E. J. (1976) *Biochim. Biophys. Acta* 452, 382–391.
- [13] Ellison, W. R., Lueck, J. D. and Fromm, H. J. (1975) *J. Biol. Chem.* 250, 1864–1871.
- [14] Gerber, G., Berger, H., Jänig, G. R. and Rapoport, S. M. (1973) *Eur. J. Biochem.* 38, 563–571.
- [15] Van Biervliet, J. P. G. and Staal, G. E. J. (1977) *Acta. Ped. Scan.* 66, 311–315.